Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 60 points (0.4%) at 16,517 as of Tuesday, April 1, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,859 issues advancing vs. 1,154 declining with 141 unchanged. The Health Care sector currently sits up 0.7% versus the S&P 500, which is up 0.4%. On the negative front, top decliners within the sector include Bristol-Myers Squibb Company ( BMY), down 1.1%, Novartis ( NVS), down 1.0%, Merck ( MRK), down 0.9%, Sanofi ( SNY), down 0.8% and Pfizer ( PFE), down 0.8%. Top gainers within the sector include Celgene Corporation ( CELG), up 3.5%, Gilead ( GILD), up 3.4%, Illumina ( ILMN), up 3.4%, Quest Diagnostics ( DGX), up 3.3% and Regeneron Pharmaceuticals ( REGN), up 2.6%. TheStreet would like to highlight 3 stocks pushing the sector lower today: 3. Medicines Company ( MDCO) is one of the companies pushing the Health Care sector lower today. As of noon trading, Medicines Company is down $4.31 (-15.2%) to $24.11 on heavy volume. Thus far, 6.1 million shares of Medicines Company exchanged hands as compared to its average daily volume of 971,600 shares. The stock has ranged in price between $23.53-$24.69 after having opened the day at $23.89 as compared to the previous trading day's close of $28.42. The Medicines Company provides medical solutions for patients in acute and intensive care hospitals worldwide. Medicines Company has a market cap of $1.8 billion and is part of the drugs industry. Shares are down 26.4% year-to-date as of the close of trading on Monday. Currently there are 5 analysts that rate Medicines Company a buy, no analysts rate it a sell, and 2 rate it a hold. TheStreet Ratings rates Medicines Company as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, feeble growth in the company's earnings per share and deteriorating net income. Get the full Medicines Company Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.